| Enzalutamide with standard first-line therapy in metastatic prostate cancer ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ... New England Journal of Medicine 381 (2), 121-131, 2019 | 1308 | 2019 |
| Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised … C Eng, TW Kim, J Bendell, G Argilés, NC Tebbutt, M Di Bartolomeo, ... The lancet oncology 20 (6), 849-861, 2019 | 471 | 2019 |
| First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE … HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ... The Lancet Oncology 18 (9), 1159-1171, 2017 | 391 | 2017 |
| Denosumab and bone metastasis–free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time MR Smith, F Saad, S Oudard, N Shore, K Fizazi, P Sieber, B Tombal, ... Journal of Clinical Oncology 31 (30), 3800-3806, 2013 | 279 | 2013 |
| Evaluation of the Cockroft–Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients GM Marx, GM Blake, E Galani, CB Steer, SE Harper, KL Adamson, ... Annals of oncology 15 (2), 291-295, 2004 | 172 | 2004 |
| Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ... Journal of Clinical Oncology 41 (18), 3339-3351, 2023 | 164 | 2023 |
| Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer HM Lin, L Castillo, KL Mahon, K Chiam, BY Lee, Q Nguyen, MJ Boyer, ... British journal of cancer 110 (10), 2462-2471, 2014 | 149 | 2014 |
| Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme GM Marx, N Pavlakis, S McCowatt, FM Boyle, JA Levi, DR Bell, R Cook, ... Journal of neuro-oncology 54, 31-38, 2001 | 149 | 2001 |
| Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer AC Won, H Gurney, G Marx, P De Souza, MI Patel BJU Int 112 (4), E250-E255, 2013 | 136 | 2013 |
| Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial MR Smith, HI Scher, S Sandhu, E Efstathiou, PN Lara, YY Evan, ... The Lancet Oncology 23 (3), 362-373, 2022 | 135 | 2022 |
| Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling L Zhao, BY Lee, DA Brown, MP Molloy, GM Marx, N Pavlakis, MJ Boyer, ... Cancer research 69 (19), 7696-7703, 2009 | 132 | 2009 |
| ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Enzalutamide with standard first-line therapy in metastatic prostate … ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ... N Engl J Med 381 (2), 121-131, 2019 | 120 | 2019 |
| Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab … R Von Moos, JJ Body, B Egerdie, A Stopeck, JE Brown, D Damyanov, ... Supportive Care in Cancer 21, 3497-3507, 2013 | 108 | 2013 |
| Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial CH Barcenas, SA Hurvitz, JA Di Palma, R Bose, AJ Chien, N Iannotti, ... Annals of Oncology 31 (9), 1223-1230, 2020 | 106 | 2020 |
| Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer KL Mahon, W Qu, J Devaney, C Paul, L Castillo, RJ Wykes, MD Chatfield, ... British journal of cancer 111 (9), 1802-1809, 2014 | 99 | 2014 |
| Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases R von Moos, JJ Body, B Egerdie, A Stopeck, J Brown, L Fallowfield, ... Supportive Care in Cancer 24, 1327-1337, 2016 | 87 | 2016 |
| Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! GM Marx, CB Steer, P Harper, N Pavlakis, O Rixe, D Khayat Journal of clinical oncology 20 (6), 1446-1448, 2002 | 82 | 2002 |
| Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an … CJ Sweeney, AJ Martin, MR Stockler, S Begbie, L Cheung, KN Chi, ... The Lancet Oncology 24 (4), 323-334, 2023 | 80 | 2023 |
| Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy … P Gibbs, V Heinemann, NK Sharma, J Taieb, J Ricke, M Peeters, ... Clinical colorectal cancer 17 (4), e617-e629, 2018 | 72 | 2018 |
| Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer KL Mahon, HM Lin, L Castillo, BY Lee, M Lee-Ng, MD Chatfield, K Chiam, ... British journal of cancer 112 (8), 1340-1348, 2015 | 72 | 2015 |